Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TUL011018
- Development stage
- Phase 2
- Lead developer
- United Lab
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
TUL011018 is a small molecule Janus kinase 1 (JAK1) inhibitor, initially developed by Zhuhai United Pharmaceutical Co.,Ltd. It demonstrates high potency for JAK1 with an IC50 value of 3 nM and exhibits significant selectivity over JAK2 and TYK2. The drug has shown effective activity in preclinical models of rheumatoid arthritis (RA) and is currently being investigated for its therapeutic potential in atopic dermatitis.
- Brand names
- TUL01101TUL-01101TUL 01101
- Other names
- TUL01101 ointmentTUL-01101 ointmentTUL 01101 ointmentcompound 36 (in medicinal chemistry literature)
02
Targets
JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on TUL011018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TUL011018.